Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H27NO4S.ClH |
| Molecular Weight | 401.948 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[S@@+]([O-])CC[C@](CO)(C(=O)O[C@H]1CN2CCC1CC2)C3=CC=CC=C3
InChI
InChIKey=QHXPHLKFVDPMLS-XPTPVYCOSA-N
InChI=1S/C19H27NO4S.ClH/c1-25(23)12-9-19(14-21,16-5-3-2-4-6-16)18(22)24-17-13-20-10-7-15(17)8-11-20;/h2-6,15,17,21H,7-14H2,1H3;1H/t17-,19+,25+;/m0./s1
Revatropate is a muscarinic antagonist with selectivity for M1 and M3 receptor subtypes. Significant improvement in airway function was shown in horses with heaves after inhalation of revatropate, and it was found to be a safe and effective bronchodilator. Early clinical studies in chronic obstructive airway disease (COAD) patients also showed that inhaled revatropate was an effective bronchodilator, and well tolerated.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
586346-96-5
Created by
admin on Sat Dec 16 11:49:14 GMT 2023 , Edited by admin on Sat Dec 16 11:49:14 GMT 2023
|
PRIMARY | |||
|
69110544
Created by
admin on Sat Dec 16 11:49:14 GMT 2023 , Edited by admin on Sat Dec 16 11:49:14 GMT 2023
|
PRIMARY | |||
|
BJ9G601BQR
Created by
admin on Sat Dec 16 11:49:14 GMT 2023 , Edited by admin on Sat Dec 16 11:49:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
